|
Iniesta-Navalón C, Urbieta-Sanz E, Gascón-Cánovas JJ, Rentero-Redondo L, Cabello Muriel A, García-Molina C. [Risk prescription associated to treatment at home of the elderly patient when admitted to the hospital]. Farm Hosp. 2013 Mar-Apr;37(2):156-60. doi: 10.7399/FH.2013.37.2.461. Spanish. PubMed PMID: 23789760.
AÑO: 2013
|
23789760
|
Cabello-Muriel A, Urbieta-Sanz E, Iniesta-Navalón C, García-Molina C, Rentero-Redondo L, Antequera-Lardón T. [Follow-up of analytical parameters in Internal Medicine patients to detect adverse events]. Farm Hosp. 2013 Jan-Feb;37(1):35-40. doi: 10.7399/FH.2013.37.1.59. Spanish. PubMed PMID: 23461498.
AÑO: 2013
|
|
Iniesta Navalón C, Urbieta Sanz E, Gascón Cánovas JJ, Madrigal de Torres M. [Inadequate prescription of drugs in the elderly]. Rev Clin Esp. 2012 May;212(5):268-70. doi: 10.1016/j.rce.2011.11.009. Epub 2012 Jan 20. Spanish. PubMed PMID: 22264770.
AÑO: 2012; IF: 1.304
|
|
Diaz LS, Navalon CI, Espin RG, Prado IN, Redondo LR. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023 Aug-Sep;46(7):504-511. doi: 10.1016/j.gastrohep.2022.10.019. Epub 2022 Nov 15. English, Spanish. PubMed PMID: 36400260.
AÑO: 2023; IF: 2.2
|
|
Iniesta Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2024 Dec 4. doi: 10.17235/reed.2024.10521/2024. Online ahead of print. PubMed PMID: 39629805.
AÑO: 2024; IF: 2.7
|